Related references
Note: Only part of the references are listed.Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Sabine Kahl et al.
DIABETES CARE (2020)
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
Mariam Alatrach et al.
DIABETES (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion
Carolina Solis-Herrera et al.
DIABETES CARE (2020)
Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
Mitsuhiro Kawakubo et al.
SCIENTIFIC REPORTS (2020)
Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus
Seo H. Baik et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy
Giuseppe Daniele et al.
DIABETOLOGIA (2020)
Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes
Peter J. Thompson et al.
CELL METABOLISM (2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Aino Latva-Rasku et al.
DIABETES CARE (2019)
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
FRONTIERS IN ENDOCRINOLOGY (2019)
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
Christian Anholm et al.
DIABETOLOGY & METABOLIC SYNDROME (2019)
Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
John M. Dennis et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study
Oana P. Zaharia et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Cellular senescence: at the nexus between ageing and diabetes
Allyson K. Palmer et al.
DIABETOLOGIA (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats
Atsuo Tahara et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Takao Sato et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy
Robert Martinez et al.
DIABETES (2018)
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
Ren Matsuba et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson et al.
DIABETOLOGIA (2018)
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study
Thomas Forst et al.
HORMONE AND METABOLIC RESEARCH (2018)
Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study
Gretha J. Boersma et al.
HORMONE AND METABOLIC RESEARCH (2018)
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Hussein Al Jobori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion
Aine M. McKillop et al.
PEPTIDES (2018)
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
Emma Ahlqvist et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effect of Lingliptin and Voglibose on metabolic Profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
Girish Parthan et al.
BMC PHARMACOLOGY & TOXICOLOGY (2018)
Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes
Yoon S. Oh et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Bernard Zinman et al.
DIABETES THERAPY (2018)
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Melissa A. Davidson et al.
CRITICAL REVIEWS IN TOXICOLOGY (2018)
Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance
Hideaki Kaneto et al.
JOURNAL OF DIABETES (2017)
Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function
Sudip Bajpeyi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Regulation of hepatic glucose metabolism in health and disease
Max C. Petersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
Tisha R. Joy et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
Elena Filipova et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans
Kasper W. ter Horst et al.
CELL REPORTS (2017)
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
Tsuyoshi Yanagimachi et al.
MOLECULAR METABOLISM (2017)
Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis
Chunguang Chen et al.
MOLECULAR METABOLISM (2017)
Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
Xiafei Lyu et al.
SCIENTIFIC REPORTS (2017)
A Decade of Genetic and Metabolomic Contributions to Type 2 Diabetes Risk Prediction
Jordi Merino et al.
CURRENT DIABETES REPORTS (2017)
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes
Francesca Santilli et al.
DIABETES CARE (2017)
The mechanisms of action of metformin
Graham Rena et al.
DIABETOLOGIA (2017)
Is Type 2 Diabetes a Glycogen Storage Disease of Pancreatic β Cells?
Frances M. Ashcroft et al.
CELL METABOLISM (2017)
Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes
Christian Anholm et al.
DIABETES OBESITY & METABOLISM (2017)
Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study
Luc Martinez et al.
ADVANCES IN THERAPY (2017)
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study
Thomas Forst et al.
DIABETES OBESITY & METABOLISM (2017)
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
Elza Muscelli et al.
DIABETOLOGIA (2016)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
Lydia Lynch et al.
CELL METABOLISM (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele et al.
DIABETES CARE (2016)
When β-cells fail: lessons from dedifferentiation
D. Accili et al.
DIABETES OBESITY & METABOLISM (2016)
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
A. Dutour et al.
DIABETES OBESITY & METABOLISM (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues
Vanessa Pellegrinelli et al.
DIABETOLOGIA (2016)
Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial
Daniel H. van Raalte et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Exenatide Improves Both Hepatic and Adipose Tissue Insulin Resistance: A Dynamic Positron Emission Tomography Study
Amalia Gastaldelli et al.
HEPATOLOGY (2016)
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW
Devjit Tripathy et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong et al.
JOURNAL OF HEPATOLOGY (2016)
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Manoela Mota et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Allyson K. Palmer et al.
DIABETES (2015)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2015)
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
B. Bode et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Canaglif lozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
Lawrence A. Leiter et al.
DIABETES CARE (2015)
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
Muhammad A. Abdul-Ghani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
Benedikt A. Aulinger et al.
DIABETES (2014)
Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial
Ravi Retnakaran et al.
DIABETES CARE (2014)
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2014)
Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
Sunder Mudaliar et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation
Giuseppe Derosa et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2014)
Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
Andreas L. Birkenfeld et al.
HEPATOLOGY (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Rachel J. Perry et al.
NATURE (2014)
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis
Thomas Klein et al.
MEDICAL MOLECULAR MORPHOLOGY (2014)
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Bogna Grygiel-Gorniak
NUTRITION JOURNAL (2014)
MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice
Tatsuya Ohyama et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes
E. Phielix et al.
DIABETES OBESITY & METABOLISM (2013)
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model
B. A. Omar et al.
DIABETOLOGIA (2013)
Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study
Devjit Tripathy et al.
DIABETOLOGIA (2013)
Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin
Giuseppe Derosa et al.
INTERNAL MEDICINE (2013)
Impact of Three Oral Antidiabetic Drugs on Markers of β-Cell Function in Patients with Type 2 Diabetes: A Meta-Analysis
Jin Lu et al.
PLOS ONE (2013)
Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling
Aleksey V. Matveyenko et al.
DIABETES (2012)
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
Y. -S. Lee et al.
DIABETOLOGIA (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Familial longevity is marked by enhanced insulin sensitivity
Carolien A. Wijsman et al.
AGING CELL (2011)
Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
Padma Sathyanarayana et al.
OBESITY (2011)
The Pharmacologic Basis for Clinical Differences Among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Javier Morales
POSTGRADUATE MEDICINE (2011)
Effect of Pioglitazone on Energy Intake and Ghrelin in Diabetic Patients
Corby K. Martin et al.
DIABETES CARE (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Beata Lecka-Czernik
Current Osteoporosis Reports (2010)
Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
Amalia Gastaldelli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
The Randle cycle revisited: a new head for an old hat
Louis Hue et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
Nancy A. Thornberry et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
Rutger W. van der Meer et al.
CIRCULATION (2009)
FoxO1 and hepatic lipid metabolism
Janet D. Sparks et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
The effects of glucagon-like peptide-1 on the beta cell
T. Vilsboll
DIABETES OBESITY & METABOLISM (2009)
Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)
A. J. Scheen et al.
DIABETIC MEDICINE (2009)
Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes
M. Roden et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Lipolysis and lipid mobilization in human adipose tissue
Max Lafontan et al.
PROGRESS IN LIPID RESEARCH (2009)
Selective versus total insulin resistance: A pathogenic paradox
Michael S. Brown et al.
CELL METABOLISM (2008)
Poglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content
Balasubramanian Ravikumar et al.
DIABETES (2008)
Beneficial Effects of Insulin on Glycemic Control and β-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy
Harn-Shen Chen et al.
DIABETES CARE (2008)
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data
Rebecca J. Brown et al.
PEDIATRIC DIABETES (2008)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes
Ivana Zib et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2007)
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Amalia Gastaldelli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Overproduction of large VLDL particles is driven by increased liver fat content in man
M Adiels et al.
DIABETOLOGIA (2006)
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
A Natali et al.
DIABETOLOGIA (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue
N Rasouli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance
WH Herman et al.
ANNALS OF INTERNAL MEDICINE (2005)
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients
Y Miyazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study
TM Wallace et al.
DIABETIC MEDICINE (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
E Chiquette et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
PPAR and immune system - what do we know?
X Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats
JA Pospisilik et al.
DIABETES (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Pulsatile insulin secretion: Detection, regulation, and role in diabetes
N Porksen et al.
DIABETES (2002)
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
Y Miyazaki et al.
DIABETES CARE (2002)
The mode of action of thiazolidinediones
H Hauner
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
Y Miyazaki et al.
DIABETES CARE (2001)
Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells
M Dubois et al.
DIABETOLOGIA (2000)
Share Paper
